Composite pheochromocytoma/ganglioneuroma of the adrenal gland associated with multiple endocrine neoplasia 2A: case report with immunohistochemical analysis. 1997

S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts 02111, U.S.A.

We report a case of composite pheochromocytoma/ganglioneuroma arising in a background of diffuse and nodular medullary hyperplasia in the adrenal gland of a 34-year-old man with multiple endocrine neoplasia 2a (MEN 2a). Cells were histologically classified as chromaffin or chromaffin-like (small typical-appearing pheochromocytoma cells), neuron-like (possessing ganglion cell morphology), and intermediate. We speculate that these cell types may represent a spectrum of differentiation of a neoplastic clone, with the intermediate cells representing a transitional stage between chromaffin cells and neurons. All three cell types in the composite tumor and all chromaffin cells in both nodular and nonnodular areas of the remaining medulla were strongly immunoreactive for tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis. In contrast, neuron-like cells (and to a variable extent intermediate cells) displayed selective loss of expression of phenylethanolamine-N-methyltransferase (PNMT), the enzyme that synthesizes epinephrine. Proliferative activity of the composite tumor and both the nodular and nonnodular medulla was studied by staining for the endogenous cell proliferation antigen Ki-67, using monoclonal antibody MIB-1. MIB-1 labeling was highest in Schwann cell areas of the composite tumor, followed by chromaffin-like cells in the composite tumor and in the separate nodules. Labeling was absent in neuron-like cells, consistent with the cells' postulated status as terminally differentiated derivatives of a chromaffin cell precursor, and was highly variable in nonnodular areas of the medulla. The latter observation suggests topographical variation in signals that drive chromaffin cell proliferation in MEN.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D005729 Ganglioneuroma A benign neoplasm that usually arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. The tumor may present clinically with HORNER SYNDROME or diarrhea due to ectopic production of vasoactive intestinal peptide. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p966) Gangliocytoma,Gangliocytomas,Ganglioneuromas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018813 Multiple Endocrine Neoplasia Type 2a A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease. MEN 2,MEN 2a,Neoplasia, Multiple Endocrine Type 2a,Neoplasms, Multiple Endocrine Type 2a,Sipple Syndrome,MEA 2a,MEA II,MEA IIa,MEN II,MEN IIa,MEN-2A Syndrome,MEN2a,Multiple Endocrine Neoplasia Type 2,Multiple Endocrine Neoplasia, Type IIa,Multiple Endocrine Neoplasms Type 2a,Pheochromocytoma And Amyloid-Producing Medullary Thyroid Carcinoma,MEN 2A Syndrome,MEN-2A Syndromes,Pheochromocytoma And Amyloid Producing Medullary Thyroid Carcinoma

Related Publications

S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
April 2013, Urology annals,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
August 1998, Hinyokika kiyo. Acta urologica Japonica,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
August 2017, Journal of medical case reports,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
September 2005, Journal of endocrinological investigation,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
June 2008, Annales de pathologie,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
October 2000, Medicina clinica,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
January 2003, Medicina,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
January 2013, Chirurgia (Bucharest, Romania : 1990),
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
October 2006, Saudi medical journal,
S Brady, and R M Lechan, and S D Schwaitzberg, and Y Dayal, and J Ziar, and A S Tischler
August 1996, Ceskoslovenska patologie,
Copied contents to your clipboard!